TY - JOUR
T1 - Epidemiology and Management of Pediatric Group A Streptococcal Pneumonia With Parapneumonic Effusion
T2 - An Observational Study
AU - Group A Streptococcal Disease Consortium
AU - Lees, Emily A.
AU - Williams, Thomas C.
AU - Marlow, Robin
AU - Fitzgerald, Felicity
AU - Jones, Christine
AU - Lyall, Hermione
AU - Bamford, Alasdair
AU - Pollock, Louisa
AU - Smith, Andrew
AU - Lamagni, Theresa
AU - Kent, Alison
AU - Whittaker, Elizabeth
AU - Riordan, Andrew
AU - Johnson, Tembe Carveth
AU - Oakley, Juliette
AU - Vergnano, Stefania
AU - Pike, Katharine
AU - Bernatoniene, Jolanta
AU - Inwald, David
AU - McShane, Trust Donna
AU - Sang, Tan Ciang
AU - Bridge, Thomas
AU - Kuek, Stephanie
AU - Farah, Sara
AU - Randle, Elise
AU - Brugha, Rossa
AU - Kadambari, Seilesh
AU - Dixon, Garth
AU - Hatcher, James
AU - Elghuwael, Ismail
AU - Bandi, Srini
AU - Koo, Sharon
AU - Adesina, Ayoade
AU - Sinha, Aditi
AU - Hoskyns, Lucy
AU - McMaster, Paddy
AU - Pillai, Anjay
AU - Kuruvilla, Grace
AU - Kilpatrick, Charlotte
AU - Davies, Trust Patrick
AU - Gordon, Sheena
AU - Fidler, Katy
AU - Kavanagh, Sarah
AU - Peto, Rebecca
AU - Kirk, Naomi
AU - Speirs, Lynne
AU - Finlay, James
AU - Longbottom, Katherine
AU - Hayes, Emily
AU - Blomquist, Paula
N1 - Publisher Copyright:
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2024/9/1
Y1 - 2024/9/1
N2 - Background: During autumn/winter 2022, UK pediatricians reported an unseasonal increase in invasive group A streptococcal infections; a striking proportion presenting with pneumonia with parapneumonic effusion. Methods: Clinicians across the United Kingdom were requested to submit pseudonymized clinical data using a standardized report form for children (<16 years) admitted between September 30, 2022 and February 17, 2023, with microbiologically confirmed group A streptococcal pneumonia with parapneumonic effusion. Results: From 185 cases submitted, the median patient age was 4.4 years, and 163 (88.1%) were previously healthy. Respiratory viral coinfection was detected on admission for 101/153 (66.0%) children using extended respiratory pathogen polymerase chain reaction panel. Molecular testing was the primary method of detecting group A streptococcus on pleural fluid (86/171; 50.3% samples). Primary surgical management was undertaken in 171 (92.4%) children; 153/171 (89.4%) had pleural drain inserted (96 with fibrinolytic agent), 14/171 (8.2%) had video-assisted thoracoscopic surgery. Fever duration after admission was prolonged (median, 12 days; interquartile range, 9-16). Intravenous antibiotic courses varied in length (median, 14 days; interquartile range, 12-21), with many children receiving multiple broad-spectrum antibiotics, although evidence for additional bacterial infection was limited. Conclusions: Most cases occurred with viral coinfection, a previously well-recognized risk with influenza and varicella zoster, highlighting the need to ensure routine vaccination coverage and progress on vaccines for other common viruses (eg, respiratory syncytial virus, human metapneumovirus) and for group A streptococcus. Molecular testing is valuable to detect viral coinfection and confirm invasive group A streptococcal diagnosis, expediting the incorporation of cases into national reporting systems. Range and duration of intravenous antibiotics administered demonstrated the need for research on the optimal duration of antimicrobials and improved stewardship.
AB - Background: During autumn/winter 2022, UK pediatricians reported an unseasonal increase in invasive group A streptococcal infections; a striking proportion presenting with pneumonia with parapneumonic effusion. Methods: Clinicians across the United Kingdom were requested to submit pseudonymized clinical data using a standardized report form for children (<16 years) admitted between September 30, 2022 and February 17, 2023, with microbiologically confirmed group A streptococcal pneumonia with parapneumonic effusion. Results: From 185 cases submitted, the median patient age was 4.4 years, and 163 (88.1%) were previously healthy. Respiratory viral coinfection was detected on admission for 101/153 (66.0%) children using extended respiratory pathogen polymerase chain reaction panel. Molecular testing was the primary method of detecting group A streptococcus on pleural fluid (86/171; 50.3% samples). Primary surgical management was undertaken in 171 (92.4%) children; 153/171 (89.4%) had pleural drain inserted (96 with fibrinolytic agent), 14/171 (8.2%) had video-assisted thoracoscopic surgery. Fever duration after admission was prolonged (median, 12 days; interquartile range, 9-16). Intravenous antibiotic courses varied in length (median, 14 days; interquartile range, 12-21), with many children receiving multiple broad-spectrum antibiotics, although evidence for additional bacterial infection was limited. Conclusions: Most cases occurred with viral coinfection, a previously well-recognized risk with influenza and varicella zoster, highlighting the need to ensure routine vaccination coverage and progress on vaccines for other common viruses (eg, respiratory syncytial virus, human metapneumovirus) and for group A streptococcus. Molecular testing is valuable to detect viral coinfection and confirm invasive group A streptococcal diagnosis, expediting the incorporation of cases into national reporting systems. Range and duration of intravenous antibiotics administered demonstrated the need for research on the optimal duration of antimicrobials and improved stewardship.
KW - Group A streptococcus
KW - antimicrobial stewardship
KW - empyema
KW - parapneumonic effusion
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85201987565&partnerID=8YFLogxK
U2 - 10.1097/INF.0000000000004418
DO - 10.1097/INF.0000000000004418
M3 - Article
C2 - 38900036
AN - SCOPUS:85201987565
SN - 0891-3668
VL - 43
SP - 841
EP - 850
JO - Pediatric Infectious Disease Journal
JF - Pediatric Infectious Disease Journal
IS - 9
ER -